NEW YORK (GenomeWeb News) – Codon Devices will work with Merrimack Pharmaceuticals to develop therapeutic proteins under a research, development, and license agreement, Codon said today.
 
Codon will use its BioLogic platform to engineer proteins for specifications set by Merrimack, which is developing therapeutic products aimed at autoimmune disease and cancer.
 
Merrimack will pay Codon clinical milestone payments and royalties on net sales of any protein products that may result from the agreement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.